Botox Research Today is a free monthly online journal that collates and summarizes the latest research about Botox, including details on cosmetic botox, side-effects, alternatives, treatment.

Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle.

de Boer KS, Arwert HJ, de Groot JH, Meskers CG, Mishre AD, Arendzen JH

Department of Rehabilitation Medicine, Leiden University Medical Centre B0-Q, PO Box 9600, 2300 RC Leiden, The Netherlands. k.s.de_boer@lumc.nl

OBJECTIVE: To study the effect of botulinum toxin A in the subscapular muscle on shoulder pain and humerus external rotation. METHODS: 22 stroke patients with spastic hemiplegia, substantial shoulder pain and reduced external rotation of the humerus participated in a randomised, double blind, placebo controlled effect study. Injections of either botulinum toxin A (Botox, 2x50 units) or placebo were applied to the subscapular muscle at two locations. Pain was scored on a 100 mm vertical Visual Analogue Scale; external rotation was recorded by means of electronic goniometry. Assessments were carried out at 0 (baseline), 6 and 12 weeks. RESULTS: 21 patients completed the study. We observed no significant changes in pain or external rotation as a result of administration of botulinum toxin A. External rotation improved significantly (p = 0.001) for both the treatment group (20.4 degrees (16.6) to 32.1 degrees (14.0)) and the control group (10.3 degrees (19.5) to 23.7 degrees (20.7)) as a function of time. CONCLUSIONS: Application of botulinum toxin A into the subscapular muscle for reduction of shoulder pain and improvement of humeral external rotation in spastic hemiplegia does not appear to be clinically efficacious.

Published 14 April 2008 in J Neurol Neurosurg Psychiatry, 79(5): 581-3.
Full-text of this article is available online (may require subscription).

Articles on Botox published 31 March 2008:

Time course analysis of the effects of botulinum toxin type a on elbow spasticity based on biomechanic and electromyographic parameters.   Arch Phys Med Rehabil, 89(4): 692-9.

OBJECTIVE: To quantify changes of elbow spasticity over time after botulinum toxin type A (BTX-A) injection in the upper extremity of stroke patients. DESIGN: Before-after trial in which the therapeutic effects were followed up at 2, 6, and 9 weeks after the BTX-A injection (Botox). SETTING: Hospital. PARTICIPANTS: Chronic stroke patients (N=8) with upper-limb spasticity. INTERVENTION: BTX-A was injected in upper-limb muscles, including the biceps brachii. MAIN OUTCOME MEASURES: Treatment ... [Abstract] [Full-text]

Articles on Botox published 3 March 2008:

Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup.   J Urol, 179(3): 1031-4.

PURPOSE: We evaluated the 1-year efficacy and tolerability of botulinum A toxin intravesically injected in patients with painful bladder symptoms associated with increased urinary frequency, refractory to conventional treatments. MATERIALS AND METHODS: Three men and 12 women were prospectively included in the study. Under short general anesthesia the patients were given injections of 200 U commercially available botulinum A toxin diluted in 20 ml 0.9% NaCl. Injections were performed ... [Abstract] [Full-text]

Articles on Botox published 25 February 2008:

The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report.   Arch Phys Med Rehabil, 89(3): 417-21.

OBJECTIVE: To describe the use of botulinum toxin type A (BTX-A) in radiation fibrosis syndrome (RFS). DESIGN: Retrospective case series. SETTING: A large tertiary care cancer center. PARTICIPANTS: Twenty-three consecutive patients treated for sequelae of RFS with BTX-A. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: A description of the components of RFS thought to benefit from BTX-A injections and the patient's self-report of benefit from those injections. RESULTS: The sequelae of RFS ... [Abstract] [Full-text]

Articles on Botox published 22 February 2008:

Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study.   Eur J Neurol, 15(3): 205-13.

Increasingly, botulinum type A toxin is used to influence pathologically increased muscle activity in conditions such as dystonia and spasticity. Studies have also assessed its efficacy in tension-type headache, where muscle tenderness may be increased. We undertook a prospective, multicentre, randomized, double-blind, placebo-controlled trial. Patients received injections of Dysport (total dose of 420 or 210 units) or saline placebo in 18 sites on the head and neck. Of 125 patients treated, ... [Abstract] [Full-text]

Articles on Botox published 5 February 2008:

Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile).   Am J Orthod Dentofacial Orthop, 133(2): 195-203.

INTRODUCTION: Previously, botulinum toxin type A (BTX-A) (Botox; Allergan, Irvine, Calif) was shown to be effective in reducing excessive gingival display in 5 patients with gummy smiles. This study was conducted to determine whether the doses and the primary injection sites used in the pilot study for the correction of gummy smiles provide consistent, statistically significant, and esthetically pleasing results. METHODS: Thirty patients received BTX-A injections to reduce excessive gingival ... [Abstract] [Full-text]

Articles on Botox published 4 February 2008:

Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.   Appl Environ Microbiol, 74(3): 653-9.

The seven serotypes of botulinum neurotoxin (BoNTs) are zinc metalloproteases that cleave and inactivate proteins critical for neurotransmission. The synaptosomal protein of 25 kDa (SNAP-25) is cleaved by BoNTs A, C, and E, while vesicle-associated membrane protein (VAMP) is the substrate for BoNTs B, D, F, and G. BoNTs not only are medically useful drugs but also are potential bioterrorist and biowarfare threat agents. Because BoNT protease activity is required for toxicity, inhibitors of that ... [Abstract] [Full-text]

Differentiation of Clostridium botulinum serotype A strains by multiple-locus variable-number tandem-repeat analysis.   Appl Environ Microbiol, 74(3): 875-82.

Ten variable-number tandem-repeat (VNTR) regions identified within the complete genomic sequence of Clostridium botulinum strain ATCC 3502 were used to characterize 59 C. botulinum strains of the botulism neurotoxin A1 (BoNT/A1) to BoNT/A4 (BoNT/A1-A4) subtypes to determine their ability to discriminate among the serotype A strains. Two strains representing each of the C. botulinum serotypes B to G, including five bivalent strains, and two strains of the closely related species Clostridium ... [Abstract] [Full-text]

Articles on Botox published 18 January 2008:

Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.   Dev Med Child Neurol, 50(2): 123-8.

The primary aim of this randomized, controlled trial was to assess the effectiveness of botulinum toxin A (BoNT-A) injections into the submandibular and parotid glands on drooling in children with cerebral palsy (CP) and other neurological disorders. Secondary aims were to ascertain the duration of any such effect and the timing of maximal response. Of the 48 participants (27 males, 21 females; mean age 11y 4mo [SD 3y 3mo], range 6-18y), 31 had a diagnosis of CP and 15 had a primary ... [Abstract] [Full-text]

© 2004-2008 Botox Research Today. All Rights Reserved.